Cytoreason 融资 https://www.sohu.com/a/588334030_139908 CytoReason and Pfizer sign $110M Deal CytoReason, Pfizer ink $110M extension of AI collab https://www.crunchbase.com/organization/cytoreason/company_financials WebFeb 10, 2022 · CytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies and uses it to simulate human diseases ... Japanese pharmaceutical firm taps Israel’s CytoReason for AI … https://www.pharmaceutical-technology.com/news/pfizer-cytoreason-extend-partnership/ WebJul 18, 2022 · 中科院孵化、亿元融资，这家AI制药公司会是中国的CytoReason吗？ 作者： 智药局- 近日，一家由中科院孵化而出的AI制药公司拿下近亿元A轮融资，进入了大众的视野。 与大部分AI制药公司不同的是，哲源科技选择从大量的医学文献和数据中，试图用 “知识+数据+超算+人工智能” 的方式分析数据，找到疾病的发病机制。 全球AI+疾病模型的初创 … WebSep 21, 2022 · 根据合作协议， 辉瑞将对CytoReason进行2,000万美元的股权投资，并获得CytoReason专有的AI技术平台和疾病模型的使用授权加速新药研发。 此外， … WebCytoreason and Summit Pharmaceuticals International forge commercial alliance to bring CytoReason’s machine learning model of the immune system for drug discovery & … Pfizer and CytoReason extend partnership for AI-driven drug … https://www.sohu.com/a/568775686_121421892 https://www.timesofisrael.com/japanese-pharmaceutical-firm-taps-israels-cytoreason-for-ai-drug-development/ https://www.pfizer.com/news/press-release/press-release-detail/cytoreason-announces-expanded-collaboration-deal-pfizer WebSep 20, 2022 · Under the terms of the agreement, Pfizer will make a $20M equity investment, have options to license CytoReason’s platform and disease models, and fund … https://www.globenewswire.com/news-release/2023/01/23/2593145/0/en/CytoReason-to-License-Its-IBD-Disease-Model-to-Sanofi-in-Expanded-Multiyear-Multimillion-Dollar-Deal.html CytoReason Collaborates with Merck KGaA, Darmstadt, Germany, … 武汉伊莱瑞特生物科技股份有限公司 - 天眼查 WebApr 12, 2022 · CytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies … CytoReason LinkedIn https://www.cytoreason.com/press-releases/ https://www.tianyancha.com/company/3014725990 https://www.prnewswire.com/news-releases/cytoreason-collaborates-with-merck-kgaa-darmstadt-germany-on-cancer-immunotherapy-drug-301404667.html WebCytoReason General Information. Description. Provider of cell-based models and data analysis services intended to develop a computational model of the human body that … CytoReason to License Its IBD Disease Model to Sanofi in https://www.cytoreason.com/ WebJan 24, 2023 · The partnership between Sanofi and CytoReason – for an undisclosed, multimillion dollar amount – forms part of an ongoing collaboration begun in 2021, which originally focused on obtaining ... WebJun 17, 2021 · About CytoReason. CytoReason's computational model of the human body simulates human disease on a cellular level, minimizes the need for animal trials, and … WebCytoReason is a tech company developing a computational model of the human body. The company collects proprietary data from pharma companies and uses it to simulate human diseases – tissue by ... Pfizer and CytoReason extend partnership for AI-driven drug … WebJul 18, 2022 · 中科院孵化、亿元融资，这家AI制药公司会是中国的CytoReason吗？ 2022-07-18 11:34 近日，一家由中科院孵化而出的AI制药公司拿下近亿元A轮融资，进入了大众的视 … CytoReason Collaborates with Sanofi, Using its AI … CytoReason Collaborates with Sanofi, Using its AI Technology to … https://finance.yahoo.com/news/cytoreason-pfizer-extend-collaboration-leverage-143000511.html https://xueqiu.com/6076022235/225617835 https://pitchbook.com/profiles/company/435026-80 https://zhuanlan.zhihu.com/p/542888834 WebJan 23, 2023 · CytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies … https://www.zoominfo.com/c/cytoreason/465341052 WebFeb 10, 2022 · CytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies and uses it to simulate human diseases ... 大健康产业投资并购动态周报Vol.114_公司_收购_交易 WebCytoReason General Information. Description. Provider of cell-based models and data analysis services intended to develop a computational model of the human body that simulates human disease on a cellular level. The company's platform uses a proprietary data and machine learning (ML) model to reconstruct cellular information from bulk tissue ... https://www.fiercebiotech.com/medtech/cytoreason-pfizer-ink-110m-five-year-extension-ai-powered-drug-development-deal WebSep 20, 2022 · Under the terms of the agreement, Pfizer will make a $20M equity investment, have options to license CytoReason’s platform and disease models, and fund … CytoReason and Pfizer sign $110M Deal 中科院孵化、拿下亿元融资，这家AI制药公司会是中国 … WebSep 20, 2022 · TEL AVIV, Israel, Sept. 20, 2022 (GLOBE NEWSWIRE) -- CytoReason today announced an extension of its multi-year partnership with Pfizer to use CytoReason’s artificial intelligence technology for ... WebCytoReason has 3 investors including Pfizer and Asymmetry Ventures. How much funding has CytoReason raised to date? CytoReason has raised … 中科院孵化、亿元融资，这家AI制药公司会是中国的CytoReason … https://www.prnewswire.com/news-releases/cytoreason-collaborates-with-sanofi-using-its-ai-technology-to-gain-better-understanding-of-disease-mechanisms-301314646.html WebJun 17, 2021 · TEL AVIV, Israel, June 17, 2021 /PRNewswire/ -- CytoReason, an AI company developing a computational disease model of the human body for clinical drug development, today announced the initiation... CytoReason - Crunchbase Company Profile & Funding WebCytoReason创立于2016年，总部位于以色列特拉维夫，基于以色列理工学院和斯坦福大学的研究而来，团队由65名计算生物学家、临床医学家、数据科学家组成， 专注免疫系统疾 … 中科院孵化、亿元融资，这家AI制药公司会是中国的CytoReason吗？ 近日，一家由中科院孵化而出的AI制药公司拿下近亿元A轮融资… WebNov 16, 2022 · 根据协议条款，辉瑞将进行2000万美元的股权投资，拥有许可CytoReason平台和疾病模型的选择权，并资助补充项目，这笔交易在未来五年内的价值可能高达1.1亿 … https://www.prnewswire.com/il/news-releases/cytoreason-expands-its-reach-in-asia-forging-commercial-alliance-with-helixrus-to-leverage-machine-learning-in-drug-development-for-korean-drugmakers-301523552.html https://www.biospace.com/article/releases/cytoreason-collaborates-with-sanofi-using-its-ai-technology-to-gain-better-understanding-of-disease-mechanisms/ Invest in CytoReason private stocks OurCrowd.com https://finance.yahoo.com/news/cytoreason-pfizer-extend-collaboration-leverage-143000511.html WebTo date, five of the world’s top ten pharma companies use CytoReason’s technology to identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval. In 2022, Pfizer signed a multi-million commercial deal to implement CytoReason’s technology across most of the organization. CytoReason and Pfizer Extend Collaboration to Leverage Machine … https://www.pharmaceutical-technology.com/news/pfizer-cytoreason-extend-partnership/ https://www.ourcrowd.com/companies/cytoreason Web天眼查为您提供武汉伊莱瑞特生物科技股份有限公司的企业信息查询服务，查询武汉伊莱瑞特生物科技股份有限公司工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营风险、公司发展状况、公司财务状况、公司股东法人高管、商标、融资、专利、法律诉讼等武汉伊莱瑞特生物科技股份 ... https://www.mobihealthnews.com/news/emea/israeli-startup-cytoreason-joins-forces-ferring-pharmaceuticals-find-new-ibd-treatment WebSep 30, 2021 · CytoReason was founded in 2016 to enable drug makers to use the computational technology it has developed as a sort of a GPS to navigate the immune system. The machine-learning software collects ... Sanofi, CytoReason expand AI deal into IBD pharmaphorum WebSep 21, 2022 · Pfizer and CytoReason have expanded their multi-year collaboration to leverage the latter’s artificial intelligence (AI) technology to discover and develop the … CytoReason Collaborates with Sanofi, Using its AI Technology to … CytoReason - Funding, Financials, Valuation & Investors https://www.biospace.com/article/releases/cytoreason-collaborates-with-sanofi-using-its-ai-technology-to-gain-better-understanding-of-disease-mechanisms/ https://info.cytoreason.com/pfizer-press-release https://www.cytoreason.com/company/ WebApr 12, 2022 · CytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies and uses it to simulate human diseases ... https://www.linkedin.com/company/cytoreason CytoReason Announces Expanded Collaboration Deal with https://pitchbook.com/profiles/company/435026-80 Press Release - Cytoreason CytoReason - Overview, News & Competitors ZoomInfo.com CytoReason Collaborates with Sanofi, Using its AI Technology to … Pfizer, CytoReason extend AI pact after immune system success https://www.sohu.com/a/586810166_121124370 WebMay 19, 2021 · Israeli startup CytoReason today announced a partnership with Swiss multinational, Ferring Pharmaceuticals, to establish new treatments for inflammatory bowel disease (IBD). This is the first … WebTo date, five of the world’s top ten pharma companies use CytoReason’s technology to identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval. … Company - Cytoreason WebCytoReason has raised a total of $20M in funding over 3 rounds. Their latest funding was raised on Sep 20, 2022 from a Corporate Round round. CytoReason is funded by 3 … https://www.prnewswire.com/news-releases/cytoreason-and-summit-pharmaceuticals-international-announce-the-introduction-of-an-ai-platform-to-one-of-japans-top-pharmaceutical-companies-301388351.html https://www.globenewswire.com/en/news-release/2022/09/20/2519131/0/en/CytoReason-Announces-Expanded-Collaboration-Deal-with-Pfizer-to-Deliver-AI-for-Drug-Discovery-and-Development.html CytoReason, Pfizer ink $110M extension of AI collab https://xueqiu.com/6076022235/225617835 CytoReason Announces Expanded Collaboration Deal … WebJun 17, 2021 · TEL AVIV, Israel, June 17, 2021 /PRNewswire/ -- CytoReason, an AI company developing a computational disease model of the human body for clinical drug … CytoReason and Pfizer Extend Collaboration to Leverage Machine … WebSep 21, 2022 · According to the deal, Pfizer will invest $20m in equity, hold options for licencing the platform and disease models of CytoReason, and provide additional funding for supporting supplementary projects. With the latest development, the partnership would be worth up to $110m over the next five years. CytoReason - Start-up Nation Finder CytoReason and Pfizer Extend Collaboration to Leverage Machine … Israeli startup CytoReason joins forces with Ferring https://cloud.tencent.com/developer/article/2165388 CytoReason and Summit Pharmaceuticals International Announce … WebCytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies and uses it to simulate human diseases - tissue by tissue, cell by cell. With CytoReason's massive database and AI-led platform, pharma and biotech companies can identify new … WebCytoReason signs multiyear, multimillion-dollar deal with Sanofi BRING DATA TO LIFE From trial and error to predictable medicine See how disease models work THE CYTOREASON DISEASE MODEL Think of it as the most … WebMar 8, 2022 · CytoReason created a platform with the potential to boost Pfizer’s understanding of the immune system by bringing together thousands of samples on a cell-protein-gene level and by seeking to address the data-insight gap through the use of machine learning. David Harel, CEO and co-founder, CytoReason ... https://www.pfizer.com/news/press-release/press-release-detail/cytoreason-announces-expanded-collaboration-deal-pfizer WebFeb 10, 2022 · CytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies … 以先进疾病模型支持药物开发｜CytoReason宣布扩大与辉瑞的合作 … https://www.outsourcing-pharma.com/Article/2022/03/08/pfizer-cytoreason-extend-ai-pact-after-immune-system-success CytoReason Expands Its Reach in Asia, Forging Commercial … WebCytoreason and Summit Pharmaceuticals International forge commercial alliance to bring CytoReason’s machine learning model of the immune system for drug discovery & development to Japanese drug makers. read more. Press Release June 17th, 2021 CytoReason Company Profile: Valuation & Investors CytoReason Company Profile: Valuation & Investors PitchBook https://www.crunchbase.com/organization/cytoreason https://www.prnewswire.com/news-releases/cytoreason-collaborates-with-sanofi-using-its-ai-technology-to-gain-better-understanding-of-disease-mechanisms-301314646.html Invest in CytoReason private stocks OurCrowd.com 【拔萃资本 被投企业新闻】CytoReason扩大与辉瑞战略合作 覆盖 … CytoReason Announces Expanded Collaboration Deal with Pfizer to Deli… https://nocamels.com/2019/05/cytoreason-immune-ai-platform-better-drugs/ https://www.cytoreason.com/press-releases/ https://pharmaphorum.com/news/sanofi-cytoreason-expand-ai-deal-into-ibd CytoReason Expands Its Reach in Asia, Forging Commercial … https://www.fiercebiotech.com/medtech/cytoreason-pfizer-ink-110m-five-year-extension-ai-powered-drug-development-deal https://www.prnewswire.com/news-releases/cytoreason-expands-its-reach-in-asia-forging-commercial-alliance-with-helixrus-to-leverage-machine-learning-in-drug-development-for-korean-drugmakers-301523552.html WebSep 30, 2021 · CytoReason's computational model of the human body simulates human disease on a cellular level, minimizes the need for animal trials, and makes human trials more focused and accurate. With ... WebMay 14, 2019 · CytoReason’s tech has so far yielded two pending patents, 10 commercial and scientific collaborations, and 16 peer-reviewed publications. Harel says it was a combination of forces that made CytoReason’s immune-focused methodology work: Big Data, machine learning, and biology. He describes it as “the intersection of computer … Home - Cytoreason WebOct 20, 2021 · CytoReason is a technology startup that has developed a computational model of the human body. The company collects proprietary data from pharmaceutical companies and uses it to simulate human... https://info.cytoreason.com/pfizer-press-release CytoReason - Crunchbase Company Profile & Funding WebSep 27, 2022 · 简述：9月22日，医疗技术公司CytoReason宣布延长与辉瑞多年的合作伙伴关系，将把CytoReason的人工智能（AI）技术用于辉瑞的药物开发计划。 根据协议条款，辉瑞将进行2000万美元的股权投资以获得CytoReason平台及其疾病模型的使用许可，并为补充项目提供资金支持。 Press Release - Cytoreason WebPfizer isn’t yet done applying CytoReason’s artificial-intelligence-powered platform and disease models to its own drug discovery and development work. Three years after the … Israeli Biotech Startup Combines Immunology, AI To Help WebCytoReason is a technology company developing a computational model of the human body that simulates human disease on a cellular level, minimizes the need for animal trials, and makes human trials more focused and accurate. https://www.ourcrowd.com/companies/cytoreason WebThe Big Pharma will start by making a $20 million equity investment in the Israeli startup; the remaining $90 million will be doled out over the next few years to fund their work together and to... 中科院孵化、亿元融资，这家AI制药公司会是中国的CytoReason … https://www.prnewswire.com/news-releases/cytoreason-and-pfizer-extend-collaboration-to-leverage-machine-learning-in-drug-development-301479737.html WebJun 17, 2021 · TEL AVIV, Israel, June 17, 2021 /PRNewswire/ -- CytoReason, an AI company developing a computational disease model of the human body for clinical drug development, today announced the initiation of a project with French global biopharmaceutical company Sanofi, which will utilize its cell-centered models and deconvolution techniques to suggest … WebJul 18, 2022 · 中科院孵化、亿元融资，这家AI制药公司会是中国的CytoReason吗？ 作者： 智药局- 近日，一家由中科院孵化而出的AI制药公司拿下近亿元A轮融资，进入了大众的视 … https://www.crunchbase.com/organization/cytoreason https://finder.startupnationcentral.org/company_page/cytoreason